A key win.
Abstract reporting of KEYNOTE-564 showed adjuvant pembrolizumab improved survival when given following gross total resection of renal cell carcinoma that is at least intermediate-high risk. | Choueiri, ASCO 2021
Search This Blog
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
- Get link
- Other Apps
Comments
Post a Comment